Home LiteratureArticle Details
PMID: 20046869 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.

PloS one ·Vol. 4 ·No. 12 ·2009-12-31 ·Pages e8534

Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC

Abstract

Epithelial ovarian cancer (EOC) is thought to arise in part from the ovarian surface epithelium (OSE); however, the molecular events underlying this transformation are poorly understood. Germline mutations in the BRCA1 tumor suppressor gene result in a significantly increased risk of developing EOC and a large proportion of sporadic EOCs display some sort of BRCA1 dysfunction. To generate a model in which Brca1-mediated transformation can be studied, we previously inactivated Brca1 alone in murine OSE, which resulted in an increased accumulation of premalignant changes, but no tumor formation. In this study, we examined tumor formation in mice with conditionally expressed alleles of Brca1, p53 and Rb, alone or in combination. Intrabursal injection of adenovirus expressing Cre recombinase to inactivate p53 resulted in tumors in 100% of mice. Tumor progression was accelerated in mice with concomitant inactivation of Brca1 and p53, but not Rb and p53. Immunohistologic analyses classified the tumors as leiomyosarcomas that may be arising from the ovarian bursa. Brca1 inactivation in primary cultures of murine OSE cells led to a suppression of proliferation that could be rescued by concomitant inactivation of p53 and/or Rb. Brca1-deficient OSE cells displayed an increased sensitivity to the DNA damaging agent cisplatin, and this effect could be modulated by inactivation of p53 and/or Rb. These results indicate that Brca1 deficiency can accelerate tumor development and alter the sensitivity of OSE cells to chemotherapeutic agents. Intrabursal delivery of adenovirus intended to alter gene expression in the ovarian surface epithelium may, in some strains of mice, result in more rapid transformation of adjacent cells, resulting in leiomyosarcomas.

MeSH Terms
Adenoviridae/genetics Animals BRCA1 Protein/genetics Cell Proliferation/drug effects Cisplatin/pharmacology Drug Screening Assays, Antitumor Epithelium/drug effects,metabolism,pathology Female Gene Silencing Humans Injections Integrases/metabolism Leiomyosarcoma/genetics,metabolism,pathology Mice Ovarian Neoplasms/genetics,metabolism,pathology Ovary/metabolism,pathology Recombination, Genetic/drug effects,genetics Retinoblastoma Protein/genetics Survival Analysis Tumor Suppressor Protein p53/genetics
Chemicals
BRCA1 Protein Retinoblastoma Protein Tumor Suppressor Protein p53 Cre recombinase Integrases Cisplatin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Clark-Knowles Katherine V
Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Senterman Mary K
Collins Olga
Vanderhyden Barbara C
References (58)
58 references, click to expand
  1. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
    Gynecol Oncol. 2006 Jan;100(1):58-64 PMID: 16137750
  2. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.
    Nat Genet. 2001 Dec;29(4):418-25 PMID: 11694875
  3. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
    Cancer. 1998 May 1;82(9):1731-7 PMID: 9576296
  4. Regulation of BRCA1 expression by the Rb-E2F pathway.
    J Biol Chem. 2000 Feb 11;275(6):4532-6 PMID: 10660629
  5. Mammary tumor formation in p53- and BRCA1-deficient mice.
    Cell Growth Differ. 1999 Jan;10(1):1-10 PMID: 9950212
  6. New insights into the pathogenesis of serous ovarian cancer and its clinical impact.
    J Clin Oncol. 2008 Nov 10;26(32):5284-93 PMID: 18854563
  7. Tumor suppressor genes and related molecules in leiomyosarcoma.
    Am J Pathol. 1996 Apr;148(4):1037-45 PMID: 8644845
  8. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.
    Nat Med. 2005 Jan;11(1):63-70 PMID: 15619626
  9. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
    Cancer Res. 2002 Jul 15;62(14):4151-6 PMID: 12124354
  10. Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse.
    Oncogene. 1998 Jul 9;17(1):1-12 PMID: 9671308
  11. E-cadherin expression in human epithelial ovarian cancer and normal ovary.
    Int J Cancer. 1997 Jun 20;74(3):275-80 PMID: 9221804
  12. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
    Nature. 1992 Mar 19;356(6366):215-21 PMID: 1552940
  13. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
    Biochem Pharmacol. 1998 Apr 15;55(8):1247-54 PMID: 9719480
  14. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.
    Nat Genet. 1999 May;22(1):37-43 PMID: 10319859
  15. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?
    Am J Surg Pathol. 2009 Mar;33(3):376-83 PMID: 19011565
  16. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
    Nat Genet. 2001 Jul;28(3):266-71 PMID: 11431698
  17. Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
    Clin Cancer Res. 1998 Oct;4(10):2433-7 PMID: 9796975
  18. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
    Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6 PMID: 17626182
  19. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.
    Nat Genet. 1997 Jul;16(3):298-302 PMID: 9207798
  20. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.
    Exp Cell Res. 2007 Jan 1;313(1):133-45 PMID: 17070800
  21. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.
    Cancer Sci. 2004 Nov;95(11):866-71 PMID: 15546503
  22. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer.
    Hum Pathol. 1999 Feb;30(2):151-7 PMID: 10029442
  23. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform.
    Genes Dev. 2003 Jan 15;17(2):201-13 PMID: 12533509
  24. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma.
    Gynecol Oncol. 2006 Apr;101(1):86-91 PMID: 16289259
  25. Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice.
    Mutat Res. 2001 Jun 2;477(1-2):183-9 PMID: 11376699
  26. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies.
    J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20 PMID: 8961970
  27. Ovarian surface epithelium: biology, endocrinology, and pathology.
    Endocr Rev. 2001 Apr;22(2):255-88 PMID: 11294827
  28. The biology of ovarian cancer.
    Semin Oncol. 1998 Jun;25(3):281-304 PMID: 9633841
  29. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
    Oncogene. 2005 May 5;24(20):3285-96 PMID: 15735702
  30. Prophylactic oophorectomy: a morphologic and immunohistochemical study.
    Cancer. 2003 Dec 15;98(12):2599-606 PMID: 14669279
  31. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy.
    Int J Gynecol Cancer. 2009 Jul;19(5):826-9 PMID: 19574767
  32. Lack of proliferative activity of surface epithelial inclusion cysts of the ovary.
    Int J Gynecol Cancer. 2003 May-Jun;13(3):303-7 PMID: 12801260
  33. Induction of apoptosis by the tumor suppressor protein BRCA1.
    Oncogene. 1996 Jul 4;13(1):1-7 PMID: 8700535
  34. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair.
    Nat Med. 1997 Jul;3(7):721-2 PMID: 9212093
  35. p53 alterations in uterine leiomyosarcomas versus leiomyomas.
    Gynecol Oncol. 1994 Aug;54(2):205-8 PMID: 8063247
  36. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway.
    Cancer Res. 1999 Apr 1;59(7 Suppl):1752s-1756s PMID: 10197592
  37. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS.
    Cell Cycle. 2004 Nov;3(11):1451-6 PMID: 15492509
  38. Caretaker Brca1: keeping the genome in the straight and narrow.
    Breast Cancer Res. 2000;2(2):82-5 PMID: 11250695
  39. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.
    Cancer Res. 2003 Jul 1;63(13):3459-63 PMID: 12839925
  40. Strain-dependent differences in malignant conversion of mouse skin tumors is an inherent property of the epidermal keratinocyte.
    Carcinogenesis. 2004 Sep;25(9):1771-8 PMID: 15105299
  41. Strain-dependent myeloid hyperplasia, growth deficiency, and accelerated cell cycle in mice lacking the Rb-related p107 gene.
    Mol Cell Biol. 1998 Dec;18(12):7455-65 PMID: 9819431
  42. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
    Ann Oncol. 1998 Apr;9(4):423-30 PMID: 9636834
  43. A role for BRCA1 in uterine leiomyosarcoma.
    Cancer Res. 2009 Nov 1;69(21):8231-5 PMID: 19843854
  44. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.
    Mol Oncol. 2009 Apr;3(2):97-137 PMID: 19383374
  45. 17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer.
    Endocrinology. 2010 Mar;151(3):929-38 PMID: 20056833
  46. A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells.
    Cancer Res. 1997 Aug 15;57(16):3351-5 PMID: 9269994
  47. Frequency of BRCA1 dysfunction in ovarian cancer.
    J Natl Cancer Inst. 2002 Jan 2;94(1):61-7 PMID: 11773283
  48. BRCA1-associated growth arrest is RB-dependent.
    Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11866-71 PMID: 10518542
  49. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers.
    Int J Cancer. 2000 Aug 1;87(3):317-21 PMID: 10897034
  50. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
    Science. 2003 Oct 24;302(5645):643-6 PMID: 14576434
  51. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review).
    Int J Oncol. 2000 Mar;16(3):567-76 PMID: 10675491
  52. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.
    Mod Pathol. 2009 Sep;22(9):1133-8 PMID: 19543244
  53. Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding.
    Oncogene. 2001 Aug 9;20(35):4827-41 PMID: 11521194
  54. Tumor spectrum analysis in p53-mutant mice.
    Curr Biol. 1994 Jan 1;4(1):1-7 PMID: 7922305
  55. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
    J Clin Pathol. 1999 May;52(5):372-5 PMID: 10560359
  56. MMTV-trBrca1 mice display strain-dependent abnormalities in vaginal development.
    Int J Dev Biol. 2004 Sep;48(7):675-8 PMID: 15470641
  57. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Cancer. 2005 Dec 15;104(12):2807-16 PMID: 16284991
  58. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours.
    Genes Chromosomes Cancer. 1999 Jun;25(2):91-6 PMID: 10337991
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
Published
2009-12-31
Epub
2009-00-31
Pages
e8534
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC2795167
Subset
IM
Grants
Canadian Institutes of Health Research · Canada
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]